Lifeward (formerly ReWalk Robotics) has officially launched its next-generation ReWalk 7 personal exoskeleton in the United States, following FDA 510(k) clearance last month. The advanced system is designed to offer a more functional and personalized walking experience for individuals with spinal cord injuries (SCI), both in personal and clinical settings.
Key Features of ReWalk 7:
- Cloud Connectivity & Customizable Speeds: Users can adjust walking speeds and benefit from seamless transitions between indoor and outdoor environments.
- Crutch and Wrist Control: A new Crutch Control feature allows users to stand, walk, select speeds, and stop with the touch of a button. Wrist Control via a smartwatch and the MyReWalk mobile app enables better control over operation modes and goal tracking.
- Enhanced Mobility: Improved battery life allows users to walk longer and more frequently, while seamless activation helps navigate stairs and curbs.
- Therapist Support: A new therapist handheld device and click-to-stop control feature ensures safer, more effective gait progression.
The ReWalk 7 is the latest milestone in Lifeward’s journey following its rebranding in 2024 to expand its product offerings. The company’s efforts were bolstered by a national reimbursement policy from CMS and previous FDA clearances for enhanced features, like the ability to use the ReWalk 6.0 system on stairs.
Follow MEDWIRE.AI for more updates on exoskeleton technologies and MedTech innovations.
